Cargando…

Personalized tumor combination therapy optimization using the single-cell transcriptome

BACKGROUND: The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcript...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Chen, Fu, Shaliu, Jin, Xuan, Li, Wannian, Xing, Feiyang, Duan, Bin, Cheng, Xiaojie, Chen, Xiaohan, Wang, Shuguang, Zhu, Chenyu, Li, Gaoyang, Chuai, Guohui, He, Yayi, Wang, Ping, Liu, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691165/
https://www.ncbi.nlm.nih.gov/pubmed/38041202
http://dx.doi.org/10.1186/s13073-023-01256-6
_version_ 1785152685945651200
author Tang, Chen
Fu, Shaliu
Jin, Xuan
Li, Wannian
Xing, Feiyang
Duan, Bin
Cheng, Xiaojie
Chen, Xiaohan
Wang, Shuguang
Zhu, Chenyu
Li, Gaoyang
Chuai, Guohui
He, Yayi
Wang, Ping
Liu, Qi
author_facet Tang, Chen
Fu, Shaliu
Jin, Xuan
Li, Wannian
Xing, Feiyang
Duan, Bin
Cheng, Xiaojie
Chen, Xiaohan
Wang, Shuguang
Zhu, Chenyu
Li, Gaoyang
Chuai, Guohui
He, Yayi
Wang, Ping
Liu, Qi
author_sort Tang, Chen
collection PubMed
description BACKGROUND: The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment. METHODS: Here, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC provides a workable solution to stratify individual patient samples based on quantitative evaluation of their personalized immune microenvironment with single-cell RNA sequencing and maximize the translational potential of in vitro cellular response to unify the identification of synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors to boost immunotherapy from a large collection of small molecules and drugs, and finally prioritize them for personalized clinical use based on bipartition graph optimization. RESULTS: We apply comboSC to publicly available 119 single-cell transcriptome data from a comprehensive set of 119 tumor samples from 15 cancer types and validate the predicted drug combination with literature evidence, mining clinical trial data, perturbation of patient-derived cell line data, and finally in-vivo samples. CONCLUSIONS: Overall, comboSC provides a feasible and one-stop computational prototype and a proof-of-concept study to predict potential drug combinations for further experimental validation and clinical usage using the single-cell transcriptome, which will facilitate and accelerate personalized tumor treatment by reducing screening time from a large drug combination space and saving valuable treatment time for individual patients. A user-friendly web server of comboSC for both clinical and research users is available at www.combosc.top. The source code is also available on GitHub at https://github.com/bm2-lab/comboSC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-023-01256-6.
format Online
Article
Text
id pubmed-10691165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106911652023-12-02 Personalized tumor combination therapy optimization using the single-cell transcriptome Tang, Chen Fu, Shaliu Jin, Xuan Li, Wannian Xing, Feiyang Duan, Bin Cheng, Xiaojie Chen, Xiaohan Wang, Shuguang Zhu, Chenyu Li, Gaoyang Chuai, Guohui He, Yayi Wang, Ping Liu, Qi Genome Med Research BACKGROUND: The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment. METHODS: Here, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC provides a workable solution to stratify individual patient samples based on quantitative evaluation of their personalized immune microenvironment with single-cell RNA sequencing and maximize the translational potential of in vitro cellular response to unify the identification of synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors to boost immunotherapy from a large collection of small molecules and drugs, and finally prioritize them for personalized clinical use based on bipartition graph optimization. RESULTS: We apply comboSC to publicly available 119 single-cell transcriptome data from a comprehensive set of 119 tumor samples from 15 cancer types and validate the predicted drug combination with literature evidence, mining clinical trial data, perturbation of patient-derived cell line data, and finally in-vivo samples. CONCLUSIONS: Overall, comboSC provides a feasible and one-stop computational prototype and a proof-of-concept study to predict potential drug combinations for further experimental validation and clinical usage using the single-cell transcriptome, which will facilitate and accelerate personalized tumor treatment by reducing screening time from a large drug combination space and saving valuable treatment time for individual patients. A user-friendly web server of comboSC for both clinical and research users is available at www.combosc.top. The source code is also available on GitHub at https://github.com/bm2-lab/comboSC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-023-01256-6. BioMed Central 2023-12-01 /pmc/articles/PMC10691165/ /pubmed/38041202 http://dx.doi.org/10.1186/s13073-023-01256-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tang, Chen
Fu, Shaliu
Jin, Xuan
Li, Wannian
Xing, Feiyang
Duan, Bin
Cheng, Xiaojie
Chen, Xiaohan
Wang, Shuguang
Zhu, Chenyu
Li, Gaoyang
Chuai, Guohui
He, Yayi
Wang, Ping
Liu, Qi
Personalized tumor combination therapy optimization using the single-cell transcriptome
title Personalized tumor combination therapy optimization using the single-cell transcriptome
title_full Personalized tumor combination therapy optimization using the single-cell transcriptome
title_fullStr Personalized tumor combination therapy optimization using the single-cell transcriptome
title_full_unstemmed Personalized tumor combination therapy optimization using the single-cell transcriptome
title_short Personalized tumor combination therapy optimization using the single-cell transcriptome
title_sort personalized tumor combination therapy optimization using the single-cell transcriptome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691165/
https://www.ncbi.nlm.nih.gov/pubmed/38041202
http://dx.doi.org/10.1186/s13073-023-01256-6
work_keys_str_mv AT tangchen personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT fushaliu personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT jinxuan personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT liwannian personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT xingfeiyang personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT duanbin personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT chengxiaojie personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT chenxiaohan personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT wangshuguang personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT zhuchenyu personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT ligaoyang personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT chuaiguohui personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT heyayi personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT wangping personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome
AT liuqi personalizedtumorcombinationtherapyoptimizationusingthesinglecelltranscriptome